Cargando…

A novel immunotherapy for superficial bladder cancer by intravesical immobilization of GM-CSF

In situ gene therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF) was demonstrated to successfully inhibit tumour cell growth in a mouse orthotopic bladder cancer model, but suffered from several disadvantages, such as limited efficiency for gene delivery, low expression efficiency...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Zhiming, Tan, Wanlong, Zhang, Lin, Liang, Zhongkun, Xu, Cuixiang, Su, Hua, Lu, Jianxin, Gao, Jimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2010
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829043/ https://www.ncbi.nlm.nih.gov/pubmed/19627402 http://dx.doi.org/10.1111/j.1582-4934.2009.00818.x

Ejemplares similares

Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer
por: Rangsitratkul, Coby, et al.
Publicado: (2022)

Sequential administration of anti-PD-1 and anti-Tim-3 combined with an SA-GM-CSF-anchored vaccine overcomes adaptive immune resistance to reject established bladder cancer
por: Zhang, Xinji, et al.
Publicado: (2021)

PD-1 Blockade Overcomes Adaptive Immune Resistance in Treatment with Anchored-GM-CSF Bladder Cancer Cells Vaccine
por: Zhang, Xinji, et al.
Publicado: (2018)

Intravesical immunotherapy in nonmuscle invasive bladder cancer
por: Jokisch, Jan-Friedrich, et al.
Publicado: (2015)

GM-CSF: A Double-Edged Sword in Cancer Immunotherapy
por: Kumar, Anil, et al.
Publicado: (2022)

Phase I Neoadjuvant Study of Intravesical Recombinant Fowlpox-GM-CSF (rF-GMCSF) or Fowlpox-TRICOM (rF-TRICOM) in Patients with Bladder Carcinoma
por: Portal, Daniella E., et al.
Publicado: (2019)

Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma
por: Ord, J J, et al.
Publicado: (2005)

GM-CSF in inflammation
por: Hamilton, John A.
Publicado: (2019)

Norcantharidin enhances antitumor immunity of GM‐CSF prostate cancer cells vaccine by inducing apoptosis of regulatory T cells
por: Mo, Lijun, et al.
Publicado: (2018)

Role of GM-CSF in lung balance and disease
por: Chen, Yingzi, et al.
Publicado: (2023)

Bladder Sparing Therapy for BCG Failures – I – Intravesical Immunotherapy
por: Messing, Edward M.
Publicado: (2017)

G-CSF and GM-CSF in clinical trials.
por: Antman, K. H.
Publicado: (1990)

Intravesical therapy in the management of superficial transitional cell carcinoma of the bladder: the experience of the EORTC GU Group.
por: Newling, D.
Publicado: (1990)

Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders
por: Lazarus, Hillard M., et al.
Publicado: (2023)

Assessment of angiogenic factor, vascular endothelial growth factor, serum and urine level changes in superficial bladder tumor immunotherapy by intravesical Bacillus Calmette-Guerin
por: Kerigh, Behzad Feizzadeh, et al.
Publicado: (2010)

Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
por: Lukacs, S., et al.
Publicado: (2013)

The pilot-scale preparation of the SA-hGM-CSF bi-functional fusion protein
por: Li, Xiaoqing, et al.
Publicado: (2019)

The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer
por: Gofrit, Ofer N., et al.
Publicado: (2016)

Multisystemic BCGitis: A rare complication of intravesical BCG immunotherapy for bladder cancer
por: Vilares, Ana T., et al.
Publicado: (2022)

A role for G-CSF and GM-CSF in nonmyeloid cancers
por: Aliper, Alexander M, et al.
Publicado: (2014)

GM-CSF-Dependent Inflammatory Pathways
por: Hamilton, John A.
Publicado: (2019)

Management of BCG non-responders with fixed dose intravesical gemcitabine in superficial transitional cell carcinoma of urinary bladder
por: Mohanty, N. K., et al.
Publicado: (2008)

Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer
por: Simpson, G R, et al.
Publicado: (2012)

Disseminated Mycobacterium bovis Infection Complicating Intravesical BCG Instillation for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder
por: Elzein, Fatehi, et al.
Publicado: (2016)

G‐CSF/GM‐CSF‐induced hematopoietic dysregulation in the progression of solid tumors
por: He, Kai, et al.
Publicado: (2022)

Development of Dendritic Cells from GM-CSF(-/-) Mice in vitro : GM-CSF Enhances Production and Survival of Cells
por: Ni, Keping, et al.
Publicado: (2001)

Irradiated Bladder Cancer Cells Expressing both GM-CSF and IL-21 versus Either GM-CSF or IL-21 Alone as Tumor Vaccine in a Mouse Xenograft Model
por: Peng, Junming, et al.
Publicado: (2019)

Response to Treatment with TNFα Inhibitors in Rheumatoid Arthritis Is Associated with High Levels of GM-CSF and GM-CSF(+) T Lymphocytes
por: Bystrom, Jonas, et al.
Publicado: (2017)

Construction of Recombinant Human GM-CSF and GM-CSF-ApoA-I Fusion Protein and Evaluation of Their Biological Activity
por: Pykhtina, Mariya, et al.
Publicado: (2021)

Immunological mechanisms of intravesical chitosan/interleukin-12 immunotherapy against murine bladder cancer
por: Smith, Sean G., et al.
Publicado: (2016)

Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer
por: Liu, Yuqing, et al.
Publicado: (2019)

Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors
por: Moreo, Eduardo, et al.
Publicado: (2022)

The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: A pilot study
por: Vasudeva, Pawan, et al.
Publicado: (2008)

Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells.
por: Chung, J. Y., et al.
Publicado: (1993)

Role of urothelial cells in BCG immunotherapy for superficial bladder cancer
por: Bevers, R F M, et al.
Publicado: (2004)

Pivotal Roles of GM-CSF in Autoimmunity and Inflammation
por: Shiomi, Aoi, et al.
Publicado: (2015)

A Review of GM-CSF Therapy in Sepsis
por: Mathias, Brittany, et al.
Publicado: (2015)

The efficacy and safety of targeting GM-CSF in arthritis
por: Bykerk, Vivian P
Publicado: (2020)

GM-CSF: Orchestrating the Pulmonary Response to Infection
por: McCormick, Thomas S., et al.
Publicado: (2022)

Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment
por: Bosteels, Cedric, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l2nef3chbburf3d39b1rcoaf67